 Thus, we identified two reasonably mature CAM therapies offered and apparently utilized by our own patients, paid for by the patients and their insurance providers, believed by the practitioners to be beneficial to patients but without much solid evidence to support their use. We also know that prostate cancer patients have a high level of interest in CAM. With this in mind, we applied for and received a grant from the Advanced Medical Research Foundation and submitted a protocol to the Dana-Farber Harvard Cancer Center Internal Review Board with the primary aim of assessing the feasibility of recruiting and maintaining enrollment in CAM therapy during an 8-week course of RT and a 2-month follow-up period. Our protocol was accepted, 05-005, and is now accruing patients. 